磺酰脲类化合物的研究进展
The Development of Sulfonylurea Compounds

作者: 田 静 , 巴俊杰 :内蒙古医科大学,药学院,呼和浩特;

关键词: 磺酰脲化合物研究进展Sulfonylurea Compounds Development

摘要:
磺酰脲类化合物作为除草剂和降糖药应用于市场已经广为人知,它具有很好的生物活性及较小的毒性,在应用方面有着很多的可能性。目前,人们对磺酰脲类化合物的研究日趋增多,本文就其理化性质、合成方法以及生物活性进行了综述。

Abstract: It is well known that sulfonylurea compounds have been applied in the market as herbicides and hypoglycemic drugs. The sulfonylurea compounds have good biological activity and less toxicity, so they have a lot of possibilities in terms of application. The study of sulfonylurea compounds is increasing at present. In this paper, we summarized the physical and chemical properties, synthetic methods and biological activity of sulfonylurea compounds.

文章引用: 田 静 , 巴俊杰 (2014) 磺酰脲类化合物的研究进展。 药物化学, 2, 30-37. doi: 10.12677/HJMCe.2014.23005

参考文献

[1] 张万忠, 梁颖, 陈利, 王福兴 (2010) 一种磺酰脲类化合物的合成新工艺. 沈阳化工学院学报, 1, 28-30.

[2] 李才猛, 田庆海, 安莹, 等 (2009) 新型单取代苯磺酰内脲衍生物的合成及表征. 有机化学, 9, 1451-1467.

[3] 潘里, 刘卓, 陈有为, 等 (2013)含有单取代嘧啶的新型磺酰脲类化合物的设计、合成及除草活性. 高等学校化学学报, 6, 1416-1422.

[4] 王建华, 徐喆 (2011) 磺酰脲类药物治疗糖尿病的新进展. 齐齐哈尔医学院学报, 4, 590-591.

[5] 叶山东 (2013) 糖尿病慢性肾脏病变患者抗糖尿病药物的选择. 中华临床医师杂志, 8, 3232-3235.

[6] 高爽, 高琳 (2013) 强化血糖控制与口服降糖药合理使用诉述进展. 黑龙江科技信息, 17, 61.

[7] 陈立峰 (2012) 浅谈口服降糖药的特点与合理应用. 现代医药卫生, 22, 3482-3484.

[8] Moser, S. (2010) Analysis of Sulfonylurea Herbicides. 20th Annual Quality Assurance Conference, 19 October 2010.

[9] 孙克 (2012) 从选择性除草剂市场恢复情况分析草甘膦抗性杂草的发展. 农药, 4, 235-253.

[10] 张敏恒 (2010) 磺酰脲类除草剂的发展现状、市场与未来趋势. 农药, 4, 235-245.

[11] 杨眉, 李钰, 徐冬燕, 侯长军, 法焕宝, 霍丹群 (2014) 靶向型药物载体在抗肿瘤治疗中的研究进展. 材料导报, 3, 60-65.

[12] 许力凡, 张记, 田志强, 吴玉章 (2013) 肿瘤抗药性的表观遗传学调控机制. 基础医学与临床, 12, 1638-1641.

[13] Chern, J.W., Leu, Y.L., Wang, S.S., Jou, R., Lee, C.F., Tsou, P.C., Hsu, S.C., Liaw, Y.C. and Lin, H.M. (1997) Synthesis and cytotoxic evaluation of subs-tituted sulfony-N-hydroxyguanidine derivatives as potential antitumor agents. Journal of Medicinal Chemistry, 40, 2276-2286.

[14] Mastrolorenzo, A., Scozzafava, A. and Supuran, C.T. (2000) 4-toluenesulfonylureido derivatives of amines, amino acids and dipeptides: A novel class of potential antitumor agents. European Journal of Pharmaceutical Sciences, 11, 325- 332.

[15] Park Choo, H.Y., Lim, J.S., Kam, Y., Kim, S.Y. and Lee, J. (2001) A comparative study of quantitative structure activity relationship methods based on antitumor diarylsulfonylureas. European Journal of Medicinal Chemistry, 36, 829- 836.

[16] Kim, S., Park, J.H., Koo, S.Y., Kim, J.I., Kim, M.H., Kim, J.E., Jo, K., Choi, H.G., Lee, S.B. and Jung, S.H. (2004) Novel diarylsulfonylurea derivatives as potent antimitotic agents. Bioorganic & Medicinal Chemistry Letters, 14, 6075-6078.

[17] Hwang, H.S., Moon, E.Y., Seong, S.K., Choi, C.H., Chung, Y.H., Jung, S.H., Lee, D.K. and Yoon, S.J. (1999) Characterization of the anticancer activity of DW2282, a new anticancer agent. Anticancer Research, 19, 5087-5093.

[18] Chaudhary, G., Karthikeyan, C., Hari Narayana Moorthy, N.S. and Trivedi, P. (2008) Quantitative structure activity relationship analysis of some diarylsulphonylurea derivatives as tubulin binding agents. International Journal of Cancer Research, 4, 1-11.

[19] Kim, D.M., Won, M., Chung, C.S., Kim, S., Yim, H.J., Jung, S.H. and Jeong, S. (2010) JNK-mediated transcriptional upregulation of RhoB is critical for apoptosis of HCT-116 colon cancer cells by a novel diarylsulfonylurea derivative. Apoptosis, 15, 1540-1548.

[20] 刘卓, 潘里, 于淑晶, 李正名 (2013) N-(4'-芳环取代嘧啶基-2'-基)-2-乙氧羰基苯磺酰脲衍生物的合成及抑菌活性. 高等学校化学学报, 8, 1868-1872.

[21] 李艳艳 (2013) 甲磺隆对临床分离病原菌的抑菌作用. 解放军医学院学报, 2, 171.

[22] 巫冠中, 张文平, 吕正兵, 刘国卿 (2005) 新型磺酰脲类化合物G004对血管内皮细胞的保护作用. 中国临床药理学与治疗学, 10, 1156-1161.

[23] Sliwinska, A., Rogalska, A., Szwed, M., Kasznicki, J., Jozwiak, Z. and Drzewoski, J. (2012) Gliclazide may have an antiapoptotic effect related to its antioxidant properties in human normal and cancer cells. Molecular Biology Reports, 39, 5253-5267.

[24] Ortega, F.J., Jolkkonen, J. and Rodríguez, M.J. (2013) Microglia is an active player in how glibenclamide improves stroke outcome. Journal of Cerebral Blood Flow & Metabolism, 1-2.

[25] Ortega, F.J., Jolkkonen, J., Mahy, N. and Rodríguez, M.J. (2013) Glibenclamide enhances neurogenesis and improves long-term functional recovery after transient focal cerebral ischemia. Journal of Cerebral Blood Flow & Metabolism, 33, 356-364.

[26] Simard, J.M., Chen, M., Tarasov, K.V., Bhatta, S., Ivanova, S., Melnitchenko, L., Tsymbalyuk, N., West, G.A. and Gerzanich, V. (2006) Newly expressed SUR1-regulated NC(Ca-ATP) channel mediates cerebral edema after ischemic stroke. Nature Medicine, 12, 433-440.

[27] 张静, 于锋 (2012) 新合成磺酰脲类化合物Ⅰ4抗血小板聚集及抗血栓作用. 中国生化药物杂志, 6, 769-775.

[28] 胡瑞钺, 田波, 喻建勇 (2010) 托拉塞米的临床应用与比较探讨. 中国医药导报, 2, 189-190.

[29] Li, X.M., Jin, D.X. and Cong, H.L. (2013) Could torasemide be a prophylactic agent of contrast induced acute kidney injury? A review about this field. European Review for Medical and Pharmacological Sciences, 17, 1845-1849.

[30] 方晓江, 赵芊, 魏丽萍, 彭哲, 祝光礼, 钱宝庆 (2014) 托拉塞米治疗合并舒张性心衰的顽固性高血压临床观察. 浙江中西医结合杂志, 1, 25-27.

[31] Bugata, B.K., Dowluru, S.V.G.K.K., Rao Avupati, V., Rao Gavalapu, V., Nori, D.L.S. and Barla, S. (2013) Synthesis, characterization and in vitro biological evaluation of some new diarylsulfonylurea-chalcone hybrids as potential 5-lipoxygenase inhibitors. European Journal of Chemistry, 4, 396-401.

[32] Bugata, B.K. and Dowluru, S.V.G.K.K. (2014) QSAR and Docking Studies of Synthesized Diarylsulfonylurea Chalcone Hybrids as Anti-Inflammatory Agents. International Journal of Pharmaceutical Sciences Review and Research, 24, 144-149.

[33] Koh, G.C., Maude, R.R., Schreiber, M.F., Limmathurotsakul, D., Wiersinga, W.J., Wuthiekanun, V., Lee, S.J., Mahavanakul, W., Chaowagul, W., Chierakul, W., White, N.J., van der Poll, T., Day, N.P., Dougan, G. and Peacock, S.J. (2011) Glyburide is anti-inflammatory and associated with reduced mortality in melioidosis. Clinical Infectious Diseases, 52, 717-725.

[34] 周春燕, 唐柏彬, 郗存显, 陈冬东, 张雷, 彭涛, 王国民, 陈志琼 (2013) 固相萃取/高效液相色谱法同时测定保健食品中7种磺酰脲类降血糖药物. 分析测试学报, 10, 1212-1216.

[35] 朱荷锄 (2012) 磺酰脲类除草剂作用特点及其发展前景. 中国植保导刊, 8, 49-50.

分享
Top